Mtor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The MTOR protein (Mechanistic Target of Rapamycin) is a serine/threonine kinase that serves as a central regulator of cell growth, metabolism, and autophagy. It integrates nutritional, growth factor, and energy signals to control protein synthesis and autophagy. mTOR dysregulation is implicated in Alzheimer's disease, Parkinson's disease, and tuberous sclerosis.
| Attribute |
Value |
| Protein Name |
mTOR (Mechanistic Target of Rapamycin) |
| Gene |
MTOR |
| UniProt ID |
P42345 |
| PDB ID |
1NSG, 4J5V |
| Molecular Weight |
~289 kDa (2549 amino acids) |
| Subcellular Localization |
Cytosol, Lysosomes |
| Protein Family |
PI3K-related kinase family |
mTOR is a large protein with multiple domains:
- HEAT repeats (N-terminal)
- FAT domain
- FRB domain (FKBP12-rapamycin binding)
- Kinase domain (C-terminal)
- FATC domain
mTOR exists in two functionally distinct complexes:
- Nutrient sensing
- Protein synthesis regulation (S6K1, 4E-BP1)
- Autophagy inhibition
- Cell growth
- Actin cytoskeleton
- Cell survival (Akt activation)
- Metabolic regulation
- Autophagy Impairment: mTOR hyperactivation inhibits autophagy, leading to Aβ and tau accumulation
- Synaptic Dysfunction: mTOR regulates synaptic plasticity
- Therapeutic: Rapamycin (mTOR inhibitor) shows promise in AD models
- α-Synuclein accumulation due to impaired autophagy
- mTOR dysregulation in PD substantia nigra
- Rapamycin protects dopaminergic neurons
- TSC1/2 mutations cause mTOR hyperactivation
- mTOR inhibitors (everolimus, sirolimus) are approved
| Drug |
Mechanism |
Status |
| Rapamycin (Sirolimus) |
Allosteric mTORC1 inhibitor |
Approved for TSC |
| Everolimus |
mTORC1/2 inhibitor |
Approved for TSC |
| Torin 1 |
ATP-competitive inhibitor |
Research |
| AZ5 |
ATPD805-competitive inhibitor |
Clinical trials |
The study of Mtor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
mTOR (mechanistic Target of Rapamycin) is a serine/threonine kinase that integrates cellular signals to regulate growth and metabolism:
- Complex formation: Exists in two complexes - mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin-insensitive)
- mTORC1: Contains mTOR, Raptor, mLST8; senses nutrients, energy, growth factors
- mTORC2: Contains mTOR, Rictor, mLST8; regulates cytoskeleton and cell survival
- Signaling: Phosphorylates S6K1, 4E-BP1, ULK1, TFEB
mTOR regulates:
- Protein synthesis: Through S6K1 and 4E-BP1
- Autophagy: Inhibits autophagy through ULK1 and TFEB phosphorylation
- Metabolism: Activates glycolysis and lipid synthesis
- Cell growth: Controls cell size and proliferation
- Alzheimer's disease: mTOR hyperactivation impairs autophagy; contributes to Aβ and tau accumulation
- Parkinson's disease: mTOR dysregulation affects α-synuclein clearance
- ALS: mTOR signaling altered in motor neurons
- Therapeutic: Rapamycin and analogs (rapalogs) in clinical trials
- Rapamycin/Sirolimus: Allosteric mTORC1 inhibitor
- AZD8055: ATP-competitive mTOR inhibitor
- Dual mTORC1/2 inhibitors: Torin 1, AZD8055
- mTOR + autophagy: Combinatorial approaches